ASTCT Nucleus > ASTCT News
03.30.23 by Nirali Shah, MD, MHSc 03.28.23 by Betty Ky Hamilton, MD 03.24.23 by Nandita Khera, MD, MPH 03.23.23 by Kirsten Williams, MD 03.21.23 by Alison Gulbis, PharmD,…
03.30.23 by Nirali Shah, MD, MHSc 03.28.23 by Betty Ky Hamilton, MD 03.24.23 by Nandita Khera, MD, MPH 03.23.23 by Kirsten Williams, MD 03.21.23 by Alison Gulbis, PharmD,…
The Pharmacy HCT Core Topics Live Session will air on Wednesday, May 8, at 2 pm CT/3 pm ET. This live session will focus on…
Introduction: Advanced Practice Providers (APPs) play a crucial role in the functioning of transplant and cellular therapy programs of all sizes. Physician Assistant and Nurse…
The number of long-term survivors of hematopoietic cell transplantation (HCT) and cellular therapy is rapidly expanding. Guidelines for the screening and preventative practices for HCT…
Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation. This study seeks…
Program Description: Articles designated for CME credit are designed to be the next step in the process of translating clinically relevant, evidence-based recommendations into clinical…
The number of long-term survivors of hematopoietic cell transplantation (HCT) and cellular therapy is rapidly expanding. Guidelines for the screening and preventative practices for HCT…
On April 10, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the fiscal year (FY) 2025 Medicare hospital inpatient prospective payment system (IPPS)…
This webinar is the first in a series of three presented by the ASTCT Palliative Care SIG. The speakers will share their insight as to…
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,600 physicians, investigators and other health care professionals…
The Food and Drug Administration approves CAR T-Cell therapy Abecma as a second-line treatment and the CAR T-Cell therapy Carvykti as a third-line treatment for…